Adult Vaccines Market - Global Industry Insights, Trends, Outlook, and Analysis Forecast from 2017 to 2025

Vaccination is one of the most effective and safest therapy that protects from diseases and reduces the prevalence of infectious diseases. There are rare side effects associated with vaccinations. Most of the vaccines are recommended on the basis of person’s age, lifestyle, travel destinations, and health conditions such as diabetes, heart diseases, asthma, and chronic obstructive pulmonary disease (COPD). According to Centers for Disease Control and Prevention (CDC), in 2013, around 226,000 people are hospitalized every year and between 3,000 and 49,000 people die due to influenza and its complications, with major population of adults. Moreover, around 900,000 people are infected by pneumococcal pneumonia every year, among which, around 400,000 people get hospitalized and 19,000 people die, and around one million cases of shingles occur annually. CDC estimated that financial burden of adult vaccine preventable diseases (VPD) in the U.S. at around US$ 10 billion annually. However, CDC recommends that adult must be vaccinated against various infections such as influenza, pertussis (whooping cough), chickenpox, diphtheria, measles, hepatitis A and B, meningococcal disease (meningitis), human papillomavirus, mumps, pneumococcal disease (pneumonia), rubella, shingles, and tetanus.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1091

Global Adult Vaccines Market Taxonomy

By Types of Vaccines – Monovalent,Multivalent,.

By Technology – Live Attenuated Vaccines,Inactivated Viral Or Bacterial Vaccines,Toxoid Vaccines,Recombinant Vaccines,Conjugate Vaccines,.

Route of Administration – Subcutaneous (SC),Intramuscular (IM),Others,.

Initiatives by state authorities against viral and bacterial infections and innovation of novel vaccines is expected to fuel growth of the market

In August 2017, GlaxoSmithKline and Ali health promoted HPV/Cervarix – which is a part of online shopping program named Taobao. It offer many features, which include pediatric and adult vaccine information and links of 1500 health clinics for consultations and appointments in China. This in turn, is expected to fuel growth of the adult vaccine market in the near future. Moreover, Dallas County Health and Human Services (DCHHS), in August 2017, is offering seasonal flu vaccine for adults. It provides all-in-one shot vaccine for multiple flu strains, including H1N1, after recommended by CDC for flu prevention. Thus, various initiatives by the health authority reduces flu impact in the U.S., which in turn, is expected to fuel growth of the adult vaccines market.

Request Customization: https://www.coherentmarketinsights.com/insight/request-customization/1091

In 2016, Protein Science Corporation announced 2016/17 formulation of Flubok influenza vaccine approved by FDA for 18 years and above.

According to Public Health England (PHE), in September 2017, it was reported that vaccine shot given for influenza were ineffective in patients over 65 years of age, as it was inactivated form of vaccine. However, nasal influenza vaccine reduced risk of influenza in children. PHS suggest the development of new vaccines, which may provide better protection from infections in geriatric population. Thus, it provides an opportunity to key players operating in adult vaccine market to develop effective vaccines for geriatric population.

In 2017, World Health organization (WHO) published a list of candidate vaccines in development for seven pathogen areas such as HIV, malaria, tuberculosis, Shigella, Respiratory Syncytial Virus (RSV), Enterotoxigenic E. Coli (ETEC), and Norovirus. Development of new vaccines against range of severe infections, is expected to propel growth of the adult vaccine in the near future.

Increasing prevalence of viral or bacterial communicable and non-communicable infections in adults, fuels growth of the adult vaccine market

According to the Immunization Action Coalition (IAC), which is a member of the WHO-led project Vaccine Safety Net (VSN), an incidences took place, followed in 2017, around 166,000 cases of flu were reported in the U.S. and around 71 people died in September 2017. Moreover, in 2016, around 91,000 people were impacted from flu in last five years. Moreover, in Canada, Vancouver Coastal Health issued a warning to teens and young adults against mumps in 2017. As per IAC, February to August 2017 approximately 80 cases of mumps were reported. According to World Health Organization (WHO), in 2016, pregnant women and elder individual, aged 65 years and above, and health workers are always at higher risk of infections. Moreover, according to CDC, people traveling for vacations every year for business and volunteerism have higher risk for development of infections. Vaccination is made compulsory for travelers by state and local health departments, which in turn, is expected to fuel growth of the adult vaccines market.

Key players operating in the global adult vaccines market include GlaxoSmithKline, plc, Panacea Biotec, Pfizer, Inc., Protein Sciences Corporation, Merck & Co., Inc., Daiichi Sankyo, Sanofi Pasteur SA, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Bavarian Nordic, CSL Limited, Serum Institute of India Pvt. Ltd., ), Emergent BioSolutions, Inc., MedImmune, LLC, and Johnson & Johnson.

To know more about the Adult Vaccines Market, click the link below: https://www.coherentmarketinsights.com/ongoing-insight/adult-vaccines-market-1091

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: http://www.coherentnews.com

This release was published on openPR.